Through modular decentralized facilities and a socially-responsible financial model, Normax says it can produce and sell mRNA vaccines at a cost of $4 per dose – a fraction of current prices. Though in its infancy, Ireland-based Normax has set-up its own mRNA UCV Consortium and developed an mRNA vaccine platform and is now looking to grow out a global manufacturing network. The company, which is looking to operate on the industry standard contract development and manufacturing organization (CDMO) business model,…